US 12029577
Neuromodulation to target glucose transporter and/or incretin pathways
granted A61PA61P1/16
Quick answer
US patent 12029577 (Neuromodulation to target glucose transporter and/or incretin pathways) held by GE Precision Healthcare LLC expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- GE Precision Healthcare LLC
- Grant date
- Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61P, A61P1/16